

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/VA8DE3593DFEN.html>

Date: August 2020

Pages: 43

Price: US\$ 125.00 (Single User License)

ID: VA8DE3593DFEN

Abstracts

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company lead product is ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the company's proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company sells ENVARSUS XR to government agencies, specialty pharmacies, managed healthcare organizations, wholesalers and retail customers across the US, Europe and worldwide. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

Jan 29,2020: Nasdaq Copenhagen has accepted Veloxis Pharmaceuticals request for Delisting of its Shares from Nasdaq Copenhagen

Nov 26,2019: Asahi Kasei offers to buy Veloxis Pharmaceuticals for \$1.3bn

Nov 12,2019: Veloxis Pharmaceuticals announces financial results for the first nine months of 2019

Aug 08,2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22,2019: Veloxis revises outlook for 2019 based on strong performance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

- Veloxis Pharmaceuticals AS - Key Facts
- Veloxis Pharmaceuticals AS - Key Employees
- Veloxis Pharmaceuticals AS - Key Employee Biographies
- Veloxis Pharmaceuticals AS - Major Products and Services
- Veloxis Pharmaceuticals AS - History
- Veloxis Pharmaceuticals AS - Company Statement
- Veloxis Pharmaceuticals AS - Locations And Subsidiaries
 - Head Office
 - Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

- Company Overview
 - Veloxis Pharmaceuticals AS - Business Description
 - Geographical Segment: Europe
 - Performance
 - Geographical Segment: Rest of the world (RoW)
 - Performance
 - Geographical Segment: United States
 - Performance
- Veloxis Pharmaceuticals AS - Corporate Strategy
- Veloxis Pharmaceuticals AS - SWOT Analysis
 - SWOT Analysis - Overview
 - Veloxis Pharmaceuticals AS - Strengths
 - Veloxis Pharmaceuticals AS - Weaknesses
 - Veloxis Pharmaceuticals AS - Opportunities
 - Veloxis Pharmaceuticals AS - Threats
 - Veloxis Pharmaceuticals AS - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Veloxis Pharmaceuticals AS, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jan 29, 2020: Nasdaq Copenhagen has accepted Veloxis Pharmaceuticals request for Delisting of its Shares from Nasdaq Copenhagen

Nov 26, 2019: Asahi Kasei offers to buy Veloxis Pharmaceuticals for \$1.3bn

Nov 12, 2019: Veloxis Pharmaceuticals announces financial results for the first nine months of 2019

Aug 08, 2019: Veloxis Pharmaceuticals announces financial results for the first six months of 2019

Jul 22, 2019: Veloxis revises outlook for 2019 based on strong performance

May 06, 2019: Veloxis Pharmaceuticals announces financial results for the first three months of 2019

Feb 27, 2019: Veloxis Pharmaceuticals releases annual report for 2018

Jan 03, 2019: Mark Hensley promoted to Chief Commercial Officer of Veloxis Pharmaceuticals

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Veloxis Pharmaceuticals AS, Key Facts
Veloxis Pharmaceuticals AS, Key Employees
Veloxis Pharmaceuticals AS, Key Employee Biographies
Veloxis Pharmaceuticals AS, Major Products and Services
Veloxis Pharmaceuticals AS, History
Veloxis Pharmaceuticals AS, Subsidiaries
Veloxis Pharmaceuticals AS, Key Competitors
Veloxis Pharmaceuticals AS, Ratios based on current share price
Veloxis Pharmaceuticals AS, Annual Ratios
Veloxis Pharmaceuticals AS, Annual Ratios (Cont...1)
Veloxis Pharmaceuticals AS, Interim Ratios
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Veloxis Pharmaceuticals AS, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Veloxis Pharmaceuticals AS, Performance Chart (2014 - 2018)

Veloxis Pharmaceuticals AS, Ratio Charts

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Veloxis Pharmaceuticals AS, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Sanofi-Aventis Canada Inc

Roche a/s

Quantum Genomics SA

Novartis Pharmaceuticals UK Ltd

Metkinen Oy

Genzyme Corp

Astellas Pharma A/S

I would like to order

Product name: Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/VA8DE3593DFEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VA8DE3593DFEN.html>